HIV-I
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) (NCT04644029) | Merck Sharp & Dohme LLC | 2021-02-24 |
| Innovation-TiFP4-C101: A Study to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-release Coformulations as Compared to an Immediate-release Coformulation of TMC114/TMC41629 (NCT00854204) | Tibotec Pharmaceuticals, Ireland | 2008-11-01 |
Track HIV-I automatically
Every clearance here is in the API, with alerts when new ones post.